Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

Abstract Background Nintedanib is effective for treating idiopathic pulmonary fibrosis (IPF), but some patients may exhibit a suboptimal response and develop on-treatment acute exacerbation (AE-IPF), hepatic injury, or mortality. It remains unclear which patients are at risk for these adverse outcom...

Full description

Bibliographic Details
Main Authors: Tang-Hsiu Huang, Chin-Wei Kuo, Chian-Wei Chen, Yau-Lin Tseng, Chao-Liang Wu, Sheng-Hsiang Lin
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Pulmonary Medicine
Subjects:
Nintedanib
Krebs von den Lungen-6
Surfactant protein A
Diffusion capacity for carbon monoxide
Acute exacerbation
Mortality
Online Access:https://doi.org/10.1186/s12890-021-01530-6

Internet

https://doi.org/10.1186/s12890-021-01530-6

Similar Items